title: The role of the cerebellum in schizophrenia: from cognition to molecular pathways.
abstract: Beside its role in motor coordination, the cerebellum is involved in cognitive function such as attention, working memory, verbal learning, and sensory discrimination. In schizophrenia, a disturbed prefronto-thalamo-cerebellar circuit has been proposed to play a role in the pathophysiology. In addition, a deficit in the glutamatergic N-methyl-D-aspartate (NMDAf) receptor has been hypothesized. The risk gene neuregulin 1 may play a major role in this process. We demonstrated a higher expression of the NMDA receptor subunit 2D in the right cerebellar regions of schizophrenia patients, which may be a secondary upregulation due to a dysfunctional receptor. In contrast, the neuregulin 1 risk variant containing at least one C-allele was associated with decreased expression of NMDA receptor subunit 2C, leading to a dysfunction of the NMDA receptor, which in turn may lead to a dysfunction of the gamma amino butyric acid (GABA) system. Accordingly, from post-mortem studies, there is accumulating evidence that GABAergic signaling is decreased in the cerebellum of schizophrenia patients. As patients in these studies are treated with antipsychotics long term, we evaluated the effect of long-term haloperidol and clozapine treatment in an animal model. We showed that clozapine may be superior to haloperidol in restoring a deficit in NMDA receptor subunit 2C expression in the cerebellum. We discuss the molecular findings in the light of the role of the cerebellum in attention and cognitive deficits in schizophrenia.
authors.affiliation: Department of Psychiatry, University of Göttingen, Göttingen, Germany.
authors.forename: Peyman
authors.initials: P
authors.lastname: Yeganeh-Doost
authors.forename: Oliver
authors.initials: O
authors.lastname: Gruber
authors.forename: Peter
authors.initials: P
authors.lastname: Falkai
authors.forename: Andrea
authors.initials: A
authors.lastname: Schmitt
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000627:therapeutic use; D002531:Cerebellum / Q000378:metabolism / Q000503:physiopathology*; D003072:Cognition Disorders / Q000503:physiopathology*; D018698:Glutamic Acid / Q000378:metabolism; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D016194:Receptors, N-Methyl-D-Aspartate / Q000378:metabolism; D012559:Schizophrenia / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology*
chemical_list: D014150:Antipsychotic Agents; D016194:Receptors, N-Methyl-D-Aspartate; D018698:Glutamic Acid; D006220:Haloperidol